Denkinger Claudia M, Kalantri Yatiraj, Schumacher Samuel G, Michael Joy S, Shankar Deepa, Saxena Arvind, Sriram Natarajan, Balamugesh Thangakunam, Luo Robert, Pollock Nira R, Pai Madhukar, Christopher Devasahayam J
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America ; McGill International TB Centre & Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Tulip Diagnostics, Goa, India.
PLoS One. 2013 Dec 23;8(12):e85447. doi: 10.1371/journal.pone.0085447. eCollection 2013.
Existing diagnostic tests for pleural tuberculosis (TB) have inadequate accuracy and/or turnaround time. Interferon-gamma (IFNg) has been identified in many studies as a biomarker for pleural TB. Our objective was to develop a lateral flow, immunochromatographic test (ICT) based on this biomarker and to evaluate the test in a clinical cohort. Because IFNg is commonly present in non-TB pleural effusions in low amounts, a diagnostic IFNg-threshold was first defined with an enzyme-linked immunosorbent assay (ELISA) for IFNg in samples from 38 patients with a confirmed clinical diagnosis (cut-off of 300 pg/ml; 94% sensitivity and 93% specificity). The ICT was then designed; however, its achievable limit of detection (5000 pg/ml) was over 10-fold higher than that of the ELISA. After several iterations in development, the prototype ICT assay for IFNg had a sensitivity of 69% (95% confidence interval (CI): 50-83) and a specificity of 94% (95% CI: 81-99%) compared to ELISA on frozen samples. Evaluation of the prototype in a prospective clinical cohort (72 patients) on fresh pleural fluid samples, in comparison to a composite reference standard (including histopathological and microbiologic test results), showed that the prototype had 65% sensitivity (95% CI: 44-83) and 89% specificity (95% CI: 74-97). Discordant results were observed in 15% of samples if testing was repeated after one freezing and thawing step. Inter-rater variability was limited (3%; 1 out of 32). In conclusion, despite an iterative development and optimization process, the performance of the IFNg ICT remained lower than what could be expected from the published literature on IFNg as a biomarker in pleural fluid. Further improvements in the limit of detection of an ICT for IFNg, and possibly combination of IFNg with other biomarkers such as adenosine deaminase, are necessary for such a test to be of value in the evaluation of pleural tuberculosis.
现有的胸膜结核诊断测试准确性不足和/或周转时间过长。在许多研究中,γ-干扰素(IFNg)已被确定为胸膜结核的生物标志物。我们的目标是基于这种生物标志物开发一种侧向流动免疫层析试验(ICT),并在临床队列中对该试验进行评估。由于IFNg在非结核性胸腔积液中通常含量较低,首先通过酶联免疫吸附测定(ELISA)对38例确诊临床诊断患者的样本中的IFNg进行检测,确定诊断性IFNg阈值(临界值为300 pg/ml;灵敏度为94%,特异性为93%)。然后设计了ICT;然而,其可达到的检测限(5000 pg/ml)比ELISA高出10倍以上。经过多次开发迭代,与ELISA检测冷冻样本相比,IFNg的ICT原型检测灵敏度为69%(95%置信区间(CI):50-83),特异性为94%(95%CI:81-99%)。与综合参考标准(包括组织病理学和微生物学检测结果)相比,在一个前瞻性临床队列(72例患者)的新鲜胸腔积液样本中对该原型进行评估,结果显示该原型的灵敏度为65%(95%CI:44-83),特异性为89%(95%CI:74-97)。如果在一次冻融步骤后重复检测,15%的样本出现了不一致的结果。评分者间的变异性有限(3%;32例中有1例)。总之,尽管经过了迭代开发和优化过程,但IFNg ICT的性能仍低于已发表文献中关于IFNg作为胸腔积液生物标志物的预期。为使这种检测方法在胸膜结核评估中具有价值,需要进一步提高IFNg ICT的检测限,并可能将IFNg与其他生物标志物如腺苷脱氨酶联合使用。